03 nov: Nye Endelige Vilkår til Nykredit Realkredit A/S' Basisprospekt af..
03 nov: Aktietilbagekøb
03-11-2017 09:26:27

ALK appoints Søren Jelert as new Chief Financial Officer

Relateret indhold
12 jun - 
C25-selskaber/Jyske: Dropper dækning af flere selskaber
08 jun - 
ALK-Abelló/SHB: Kan slippe for den værste tilskudsskræk..
06 jun - 
NKT presset af skeptiske investorer: Nu er hver syvende..
Relateret debat
12 jun - 
Naee... købte i 720 for nogle måneder siden - 50 pct.!!..
12 jun - 
Nahr - short squezze vil snarere give en endnu hurtigre..
12 jun - 
Aktien er shortet, nok derfor ?

 

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced the appointment of Søren Jelert as its new Chief Financial Officer (CFO) and Executive Vice President.

 

From 2008 until 2016, Søren Jelert, who is 45, was CFO at NNE, an engineering company that specialises in supporting pharmaceutical company engineering projects. Since 2016, he has been General Manager of NNE's US organisation. His career has also included various finance roles at Novo Nordisk and Maersk. 

 

Carsten Hellmann, ALK’s President and CEO, said: “Søren Jelert brings a wealth of experience to ALK, in particular, from his previous pharmaceutical industry-focused roles at NNE and Novo Nordisk. He has a proven track record of financial leadership and he has also played a pivotal role in transformation processes that are comparable to the one we are embarking upon at ALK.”

 

Søren will be based at ALK’s headquarters in Hørsholm, Denmark and will report directly to Carsten Hellmann. He is expected to take up his new role by 2 January 2018.

 

Søren commented: "This new role offers me the opportunity to use my knowledge and experience to support and further develop ALK as it works to build a new growth platform and to become a truly global allergy company."

 

Søren Jelert succeeds Flemming Pedersen, whose decision to leave ALK was announced in July 2017.  

 

ALK-Abelló A/S

 

For further information please contact:

Carsten Hellmann, President & CEO, tel. +45 4574 7576

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014

 

This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.

 

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/67095a20-1bd8-4156-9150-23d9b618a49d

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Vind: Tyrkiet åbner op bud på 1,2 GW havvind

22-06-2018 12:08:41
Tyrkiet har lanceret landets første budrunde på havvindenergi og har allokeret en kapacitet på 1,2 gigawatt til formålet. Myndighederne har fastlagt et loft for budprisen på 80 dollar per megawatt-time, og interesserede selskaber og konsortier skal senest 23. oktober indlevere deres bud. Støtten vil blive givet i form af en elsalgsaftale for de første 50 terawatt-timer produceret energi, skriver R..

Unibrew/Danske: Kursmålet løftes til 525 kr.

22-06-2018 10:45:53
Royal Unibrews opjustering torsdag eftermiddag har fået Danske Bank til at løfte sit kursmål for bryggeriaktien til 520 kr. fra 475 kr. Anbefalingen er uændret "hold", viser data fra Bloomberg News.Unibrews nye prognose lyder på en omsætning mellem 6,8 og 7 mia. kr., et primært driftsresultat (EBITDA) på 1550 til 1625 mio. kr. og et driftsresultat efter af- og nedskrivninger på 1190 til 1265 mio. ..

Aktier/tendens: Unibrew kan ryge op i forventet rolig markedsåbning

22-06-2018 08:07:28
En opjustering fra Royal Unibrew bliver et af fokuspunkterne i fredagens tidlige danske aktiehandel, som generelt ser ud til at ville være præget af mindre bevægelser. Efter torsdagens danske børslukning, hvor det danske C25-indeks sluttede 0,2 pct. lavere i indeks 1119,14, var der ganske vist et lille fald i de amerikanske aktier på Wall Street. Men fredag morgen er der marginale plusser i handle..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vind: Tyrkiet åbner op bud på 1,2 GW havvind
2
Aktier/middag: Unibrew indtager toppen mens Ambu igen falder tungt
3
Trump truer med told på biler fra EU - NY
4
Ørsted/Sydbank: Pris i budsejr afspejler global konkurrencesituation
5
Råvarer: Opec enige om produktionsforøgelse - olieprisen stiger

Relaterede aktiekurser

ALK-Abelló B A/S 1.068,00 -0,2% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. juni 2018 10:26:42
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180619.1 - EUROWEB5 - 2018-06-23 10:26:42 - 2018-06-23 10:26:42 - 1 - Website: OKAY